首页> 外文期刊>Kidney International Reports >Short Leukocyte Telomere Length Predicts Albuminuria Progression in Individuals With Type 2 Diabetes
【24h】

Short Leukocyte Telomere Length Predicts Albuminuria Progression in Individuals With Type 2 Diabetes

机译:短的白细胞端粒长度可预测2型糖尿病患者的蛋白尿进展。

获取原文
           

摘要

IntroductionTelomere length, a marker for biological aging, is implicated with diabetic kidney disease (DKD); however, the association between telomere length and albuminuria progression among Asian patients with type 2 diabetes (T2D) is not well understood. Here, we aim to study whether leukocyte telomere length (LTL) may independently predict albuminuria progression in patients with T2D with preserved renal filtration function (estimated GFR >60 ml/min per 1.73 m2and urine albumin-to-creatinine ratio [uACR]?<300 mg/g).MethodsThe baseline LTL was measured by real-time polymerase chain reaction in the SMART2D cohort (n?= 691) with a median follow-up of 3 years. Albuminuria progression was defined as a change in albuminuria category to a higher category and at least 30% increase in uACR from baseline in 3 years.ResultsProgressors (n?= 123) had significantly shorter median LTL compared with nonprogressors (n?= 568) (0.58 [0.38–0.79] vs. 0.62 [0.45–0.88],P?= 0.039). Compared with subjects with longer LTL (fourth quartile), subjects with shorter LTL (first quartile) had 1.93-fold (1.04–3.60,P?= 0.038) increased risk for albuminuria progression after adjustment for traditional risk factors. The association of LTL with microalbuminuria to macroalbuminuria progression was stronger than its association with normoalbuminuria to microalbuminuria (odds ratio [OR]: 1.54; 95% confidence interval [CI]: 1.02–2.32;P?= 0.042 vs. OR: 1.13; 95% CI: 0.91–1.40;P?= 0.263 per 1-SD decrement in natural log-transformed LTL).ConclusionTherefore, our results demonstrated that in patients with T2D with preserved renal filtration function, LTL predicts albuminuria progression beyond traditional risk factors, suggesting LTL may be novel biomarker for DKD progression.
机译:简介端粒长度是生物衰老的标志物,与糖尿病肾病(DKD)有关。然而,对于亚洲2型糖尿病(T2D)患者的端粒长度与蛋白尿进展之间的关联尚不甚了解。在此,我们旨在研究在保留肾脏滤过功能(估计GFR> 60 ml / min / 1.73 m2和尿白蛋白/肌酐比[uACR]?)的T2D患者中,白细胞端粒长度(LTL)是否可以独立预测白蛋白尿进展。 300 mg / g)。方法在SMART2D队列(n = 691)中通过实时聚合酶链反应测量基线LTL,平均随访3年。蛋白尿进展被定义为蛋白尿类别向更高类别的改变,并且uACR从基线开始的3年中至少增加了30%。结果与无进展者相比,进展者(n = 123)的中位LTL明显短于未进展者(n?= 568)( 0.58 [0.38-0.79]与0.62 [0.45-0.88],P?= 0.039)。与具有较长LTL(第四四分位数)的受试者相比,具有LTL较短(第一四分位数)的受试者在调整了传统危险因素后,其蛋白尿进展的风险增加了1.93倍(1.04-3.60,P?= 0.038)。 LTL与微量白蛋白尿与大白蛋白尿进展的关联要强于LTL与正常白蛋白尿与微白蛋白尿的关联(几率[OR]:1.54; 95%置信区间[CI]:1.02-2.32; P = 0.042,OR:1.13; 95) %CI:0.91–1.40;在自然对数转换的LTL中,每1-SD降低,P1 = 0.263。)因此,我们的结果表明,在具有肾滤过功能保留的T2D患者中,LTL预测白蛋白尿的进展超出了传统的危险因素,提示LTL可能是DKD进展的新型生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号